The vaccine is due to enter a Phase 1 trial in South Africa in H2, 2021. Once safety data has been received, a trial in the UK will administer the vaccine as a booster shot to people already fully vaccinated with two authorized COVID-19 vaccines.

With the DNA tech designed to accommodate multiple antigens – unlike current mRNA vaccines which incorporate a single antigen – this could be used to protect against Variants of Concern.

Green light for South Africa trial

The COVIDITY programme, focused on the Company’s novel COVID-19 vaccine candidates SCOV1 and SCOV2, is a collaboration between Scancell and scientists in the UK's newly established Centre for Research on Global Virus Infections and the new Biodiscovery Institute at the University of Nottingham, and Nottingham Trent University.

The program last week received the green light from the South African Health Products Regulatory Authority (SAHPRA) to start a Phase 1 trial in the country in H2, 2021: which will cover unvaccinated individuals. 

The objectives will be to assess the safety and immunogenicity of the two vaccine candidates, SCOV1 and SCOV2, evaluating different vaccine doses delivered by two alterative injection routes using needle-free systems (the company declined to comment further on the nature of the needle-free systems).

In addition to evaluating the virus-neutralising antibodies, the Company will also analyse the T cell responses to the N protein, which will provide additional information and data on the potential utility of both SCOV1 and SCOV2 against future SARS-CoV-2 variants.



Source link